长江商报消息 ●长江商报记者 汪静 1966年，范代娣出生在陕西省蒲城县。在蒲城的黄土塬上，年幼的范代娣常跟着做乡村医生的父亲走村 串户。父亲背着药箱半夜出诊的身影，在她心中种下了"治病救人"的种子。 1984年，范代娣以优异的成绩被西北大学无机化工专业录取，1994年，她获得华东理工大学生物化工博 士学位，成为中国生物化工专业的第一位女博士。 那时，她的前途可以说是一片辉煌，但她却先后放弃留在上海工作和出国深造的机会，揣着3000元安家 费回到西北大学，在40平方米的实验室中，在人力、物力匮乏的艰苦环境下，开始了医用大分子的探索 和研究。 从"类人胶原蛋白之母"到深陷舆论漩涡，范代娣正经历着掌舵巨子生物（02367.HK）以来最猛烈的资 本市场风暴。 5月24日，巨子生物核心产品可复美再上热搜。当日，美妆博主"大嘴博士"发文，直指巨子生物的重组 胶原蛋白精华测不出重组胶原蛋白，认为其涉嫌严重造假。当晚，巨子生物立刻发文严正驳斥并坚决否 认。 范代娣的创业史，充满科研色彩。2000年，范代娣团队突破基因工程技术，研发出全球首个"重组类人 胶原蛋白"，随后实现商业化，推出可丽金、可复美两款医美产品，直到在此轮医 ...

Core Insights - Lenovo Group reported a significant revenue increase of 21.5% year-on-year, reaching 498.5 billion RMB, marking the second-highest revenue in its history [2][3] - The net profit under non-Hong Kong financial reporting standards surged by 36% to 10.4 billion RMB [2] - Lenovo's CEO expressed pride in the company's strong performance despite external challenges, emphasizing control over its strategic direction [5][6] Financial Performance - In the fourth quarter, Lenovo's overall revenue grew by 23%, with all main business lines achieving double-digit growth [3] - The Intelligent Devices Group (IDG) saw double-digit revenue growth, while the Infrastructure Solutions Group (ISG) experienced a remarkable 63% increase, successfully turning around losses in the second half of the fiscal year [3] - The Solutions and Services Group (SSG) also reported double-digit revenue growth, with an operating profit margin exceeding 21% [3] Research and Development - Lenovo increased its R&D investment by 13% year-on-year, with R&D personnel now accounting for 27.8% of the workforce, up by 1.6 percentage points [4] Strategic Initiatives - Lenovo introduced the concept of "super intelligent agents" following the launch of its first AI PC personal intelligent agent last year [5] - The company has established a global operational system covering product design, demand forecasting, procurement, manufacturing, sales, and service [5] - Lenovo maintains a "China + N" global manufacturing strategy, leveraging China's manufacturing advantages while also establishing over 30 factories in more than ten global markets to meet local customer needs [6] Investment Activities - Lenovo's venture capital arm, Legend Capital, has invested in over 240 specialized and innovative enterprises, with 43 of these companies successfully going public [10] - Legend Capital's investment in Hanbang Technology, a leading company in the chromatography purification equipment sector, has been highlighted, with the company recently listing on the STAR Market [8][9]

荣利营造(09639)的名字正不断地与新能源产业联系到一起。日前，荣利营造(及其附属公司，统称"荣利集团")与三一集团、宁德时代(03750)携手，于香港宣 布创办零碳智能联盟与零碳智能空间，大踏步迈进香港新能源的建设与布局，不仅提出了全链企业化解决方案，更带动全行业向数字化、智能化和低碳化转 型。 在香港联交所主板IPO不足一年，荣利营造如何多措并举发轫香港新能源领域?未来又将引导主营业务作什么样的转型?投资人不禁好奇。 但能发起成立一个强者如云的新能源联盟，将三一集团、宁德时代的技术和服务引进落地，荣利营造想必有自己的过人之处。理想宏大，并逐渐付诸行动。 零碳排放蕴含巨大商机 深究方才知道，荣利营造布局新能源领域已有多时。 荣利营造植根香港20余载，早在2018年起，开始拓展光伏新能源业务;2023年率先批量使用电动工程机械，开创商用清洁能源应用先河;2024年上线4S智慧安 全工地系统，实施数字化管理。 7年来，公司涉足可再生能源业务，参与香港智慧城市建设，着手太阳能光伏系统的设计、安装及维护。目前，已为超过400家学校及NGO组织安装光伏系 统。在日积月累之下，荣利营造能发起并成立零碳智能联盟，绝非偶 ...

每经记者｜林姿辰 每经编辑｜魏官红 丨 2025年5月26日 星期一 丨 NO.3 远大医药眼科药物获中国澳门药监局批准上市 5月25日，远大医药发布公告，称用于治疗蠕形螨睑缘炎的全球创新眼科药物GPN01768（TP-03，洛替 拉纳滴眼液，0.25%）近日获得中国澳门特别行政区政府药物监督管理局批准上市。GPN01768由Tarsus Pharmaceuticals,Inc.开发，是首款也是唯一一款获得美国食品药品监督管理局（FDA）批准用于治疗蠕 形螨睑缘炎的产品，2024年在美国取得约1.8亿美元的收入，共计售出约16.3万瓶。 点评：远大医药的GPN01768（洛替拉纳滴眼液）获中国澳门药监局批准上市，且该产品是全球创新眼 科药物，去年已在美国取得约1.8亿美元收入，显示出其强大的市场潜力。 NO.4 荣昌生物回复上海证券交易所《监管问询函》 5月23日，荣昌生物发布公告，称公司于2025年4月29日收到上海证券交易所出具的《监管问询函》，并 回应了上海证券交易所关于营业收入、有息负债、产能建设、关联采购和其他方面的问题。公司表示， 2024年度产品销售毛利率与同行业公司的平均水平不存在较大差异，研 ...

公司公告汇总 鲁泰纺织股份有限公司发布了关于衍生品交易计划的可行性分析报告。公司计划开展衍生品交易业务， 主要目的是规避汇率和利率波动带来的风险。由于公司外销业务主要以美元计价，并在多个地区如香 港、越南、柬埔寨、缅甸等地设有子公司，涉及多种货币结算，同时进口设备及原辅料需支付非美元币 种，外币借款包括美元和越盾。因此，公司将通过使用远期、期货、掉期和期权等金融工具来应对这些 风险。该业务的期间为2025年7月1日至2026年6月30日，每笔衍生品期限不超过一年，总金额不超过 72356万美元。交易对象限定为具有衍生品交易业务经营资格的金融机构，资金来源为公司自有资金。 公司认为此业务具有必要性和可行性，可以降低汇率和利率波动风险，减少汇兑损失，控制经营风险， 增强财务稳健性。为此，公司已制定《鲁泰纺织股份有限公司证券投资与衍生品交易管理制度》，完善 了内控制度，配备了专业人员，并采取了多项风险控制措施，包括加强汇率研究、严格执行制度、审慎 审查合约条款、持续跟踪市场变化等。公司将依据相关会计准则对衍生品交易业务进行核算处理。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710 ...

截至2025年5月23日收盘，ST岭南(002717)报收于2.08元，上涨5.05%，换手率3.71%，成交量59.32万 手，成交额1.22亿元。 岭南生态文旅股份有限公司发布了向不特定对象发行可转换公司债券2025年度第十六次临时受托管理事 务报告。广发证券作为受托管理人，依据相关法规和协议编制了此报告。报告指出，"岭南转债"无法按 期兑付，公司现有货币资金不足以偿付本息，信用评级已下调至C级。公司2024年营业收入为86,183.66 万元，同比下滑59.55%，归属于母公司股东的净利润为-98,432.98万元；2025年一季度营业收入为 6,759.91万元，同比下滑77.85%，归属于母公司股东的净利润为-6,639.73万元。公司存在持续经营风 险，2024年审计报告被出具保留意见。为"岭南转债"提供担保的资产包括募投项目公司股权、应收款项 等，但存在变现风险和不确定性。公司面临股票退市风险，若连续20个交易日收盘价低于1元，将被终 止上市。此外，公司面临大量诉讼，截至2025年5月9日，新增尚未披露的诉讼、仲裁事项涉案金额约 17,413.36万元。广发证券将持续关注并督促公司做好信息披露， ...

Group 1 - The core viewpoint of the article highlights the increasing demand for stable value growth among investors in a volatile bond market, leading to the popularity of "fixed income +" funds [1][2] - CITIC Prudential Fund is launching a new "fixed income +" fund called CITIC Prudential Hui Li Bond, managed by Zheng Yisa, who has 14 years of industry experience and over 8 years in investment management [1] - The fund aims to combine pure bonds with selected equity public funds or ETFs to enhance returns while ensuring a good holding experience for investors [1] Group 2 - Zheng Yisa emphasizes the importance of precise duration management in the current low-interest-rate environment to systematically improve bond returns [2] - The fund will implement upper and lower limits on duration exposure based on market benchmarks to mitigate risks associated with duration [2] - The company is enhancing its trading capabilities and tools for fund managers to adapt to market challenges, focusing on optimizing product allocation and operational discipline [2]

Core Viewpoint - The beauty company, Giant Biological (02367.HK), is experiencing significant growth in performance and market capitalization, surpassing HKD 80 billion, while facing public scrutiny regarding the collagen content in its products [1][10]. Company Summary - Giant Biological's product, "Kefumei Recombined Collagen Protein Essence," was criticized by a beauty industry influencer for allegedly having a collagen content of only 0.0177%, which does not meet the regulatory requirement of being above 0.1% for non-trace ingredients [1][4]. - In response to the allegations, Giant Biological stated that their testing showed collagen content exceeding 0.1% and has engaged third-party testing agencies to verify the results [6][10]. - The company has seen its stock price and market value rise despite the controversy, indicating strong investor confidence [1][10]. Industry Summary - The controversy surrounding recombinant collagen products has sparked discussions about the effectiveness and labeling of such ingredients in the beauty industry [7][9]. - The market for recombinant collagen products is projected to grow significantly, with an expected market size of RMB 108.3 billion by 2027, and a compound annual growth rate of 55% from 2022 to 2027 [10]. - Major players in the beauty industry, including Marubi Biological and Huaxi Biological, are also entering the recombinant collagen market, indicating a competitive landscape [10].

Core Insights - The article highlights the rapid global expansion of Pop Mart, a Chinese toy brand, which has transformed from a single store in Zhongguancun to a company valued over HKD 100 billion, utilizing cultural symbols to penetrate regional barriers [1] Group 1: IP Development and Strategy - Pop Mart's core operational strategy revolves around IP (Intellectual Property), with LABUBU being a prime example of successful long-term investment and sustainable operation, leading to its global popularity [3][5] - LABUBU's success is attributed to continuous innovation in product categories, such as the introduction of plush toys that resonate with the character's theme, resulting in significant market traction [3][5] - The revenue from LABUBU's IP, part of THE MONSTES, reached CNY 3.04 billion in 2024, marking a year-on-year growth of 726.6%, making it the top revenue-generating IP for Pop Mart [5] Group 2: Cultural Adaptation and Global Strategy - Cultural adaptation is identified as a key factor in Pop Mart's international success, with the company signing local artists to cater to diverse consumer preferences [6][7] - The strategy emphasizes "global resonance and local cultivation," creating products that appeal to local consumers, such as Thai traditional clothing for LABUBU and collaborations with renowned IP companies [7] - Pop Mart's overseas revenue share increased from 15% in 2023 to 30% in the first half of 2024, with a target of reaching 55% by 2026 [7] Group 3: Market Entry and Expansion - Pop Mart's market entry strategy is based on cultural acceptance rather than GDP size, initially targeting culturally rich countries like France and the UK before expanding to Italy, the Netherlands, and Spain [8] - The opening of a store in the Louvre in Paris in 2024 marked a significant milestone, enhancing Pop Mart's global influence as the first Chinese toy brand to enter the venue [8] Group 4: Organizational Structure and Challenges - In April 2023, Pop Mart initiated its largest organizational restructuring in five years, signaling a commitment to its global strategy, with a focus on North America and Europe [9] - The company faces challenges related to international trade policies, cultural differences, and the management of a growing overseas team, which now includes over 1,000 foreign employees [9][10] - To address these challenges, Pop Mart is building a localized team in each market to ensure standardized processes and effective management [10]

本报讯(记者张敏)港股上市公司远大医药集团有限公司(以下简称"远大医药")核药管线再度释放产品利 好。近日，公司重磅创新核药产品易甘泰钇[90Y]微球注射液多项研究成果亮相美国临床肿瘤学会年会 (ASCO)以及2025年亚太原发性肝癌专家会议(APPLE)，集中展示远大医药核药产品的巨大临床潜力。 远大医药目前是全球唯四家成功实现核药商业化的企业之一。公司披露的数据显示，截至2024年末，易 甘泰钇[90Y]微球注射液已累计治疗近2000例患者，2024年实现销售收入近5亿港元。此外，远大医药在 研发注册阶段共储备了15款创新产品，涵盖68Ga、177Lu、131I、90Y、89Zr在内的5种放射性核素，覆 盖了肝癌、前列腺癌、肾癌、脑癌等在内的7个癌种。 远大医药方面人士表示，未来公司将持续加强核药抗肿瘤诊疗板块的研发和建设，丰富和完善产品管线 及产业布局，形成以易甘泰钇[90Y]微球注射液为核心的核药抗肿瘤诊疗产品集群，持续夯实公司在全 球核药抗肿瘤诊疗领域领军企业地位。 易甘泰钇[90Y]微球注射液为远大医药核药抗肿瘤诊疗板块的重磅核心产品，是全球唯一一款用于治疗 结直肠癌肝转移选择性内放射治疗(SIR ...